Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy
Open Access
- 15 July 2020
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (4) , 1
Abstract
The fibrinogen‑to‑albumin ratio (FAR), reflecting the systemic coagulation, nutritional and inflammation status of patients, has matured into a prognostic marker for several tumor types. However, only a few studies have assessed the utility of the FAR as a prognostic indicator in patients with advanced gastric cancer (GC) receiving first‑line chemotherapy. In the present study, 273 patients with advanced GC who received first‑line chemotherapy between January 2014 and January 2019 at the Cancer Hospital of China Medical University (Shenyang, China) were retrospectively analyzed. Using the cut‑off values determined by receiver operating characteristic (ROC) analysis, the patients were divided into low‑FAR (≤10.03) and high‑FAR (>10.03), low‑fibrinogen (<3.8 g/l) and high‑fibrinogen (≥3.8 g/l), and low‑albumin (<40.55 g/l) and high‑albumin (≥40.55 g/l) groups. The associations of the pretreatment FAR and clinicopathological characteristics with progression‑free survival (PFS) and overall survival (OS) were evaluated. In order to estimate the prognostic value of the FAR for patients with poor prognosis or normal fibrinogen and albumin levels, subgroup analyses were performed. The FAR had a higher area under the ROC curve (0.690; 95% CI: 0.628‑0.752; P<0.001) compared with either fibrinogen or albumin alone, which are common indicators of coagulation, nutritional and inflammatory indices. A high FAR was significantly associated with a more advanced stage, peritoneal metastasis, increased CA72‑4 levels and anemia (all P<0.05). On survival analysis, a low FAR was associated with a longer PFS and OS compared with a high FAR (202 vs. 130 days and 376 vs. 270 days, respectively; both P<0.001), while the hazard ratio (HR) and P‑values of the FAR were lower compared with those of fibrinogen and albumin alone on multivariate analysis (PFS: HR=0.638, 95% CI: 0.436‑0.932, P=0.020; OS: HR=0.568, 95% CI: 0.394‑0.819, P=0.002). Subgroup analysis indicated that among patients with poor prognosis, including multiple metastases, TNM stage IV and abnormal CA72‑4 levels, the FAR may be used as an accurate prognostic marker (all P<0.05), and may also reliably identify patients with poor prognosis among those with normal fibrinogen and albumin levels (all P<0.001). The FAR was indicated to be a valuable marker for predicting PFS and OS in patients with advanced GC receiving first‑line chemotherapy and is superior to either fibrinogen or albumin alone.Keywords
This publication has 57 references indexed in Scilit:
- Nutritional intervention for improving treatment tolerance in cancer patientsCurrent Opinion in Oncology, 2011
- Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literatureNutrition Journal, 2010
- Nutritional imbalances and infections affect the thymus: consequences on T-cell-mediated immune responsesProceedings of the Nutrition Society, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancerAnnals of Oncology, 2009
- Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinomaJournal of Experimental & Clinical Cancer Research, 2009
- Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasisNature, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Cancer-related inflammationNature, 2008
- Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cellsBlood, 2005